Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia, and can present de novo or following the early symptoms of plasma cell myeloma. Patients with PCL tend to present with aggressive clinical features, such as extramedullary disease. Here, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the challenges in treating patients with these aggressive subtypes of multiple myeloma, as optimal therapies haven’t been designed for this patient population. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.